Key facts
- It has raised $850K; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include FS Life Science Investment, Capacura, Meerkat Holding, OHA Beteiligungsgesellschaft.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Meliodays
- ·The full record, as it builds
Funding rounds
No funding rounds for Meliodays are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meliodays
Developer of an intra-uterine device designed to deliver pain medication instead of hormones. The company's device uses polymer-based technology that releases a low, localized dose of medication directly at the source of pain, reducing inflammation without systemic side effects, enabling women to use a non-hormonal system to treat period pain as a safer alternative for those who cannot use hormonal IUDs.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2022
- Employees
- 7
- Website
- meliodays.com/
- Ownership
- Privately Held (backing)
Meliodays doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meliodays shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meliodays in its N-PORT filings yet. We sweep new filings monthly.